VALSARTAN

Información principal

  • Denominación comercial:
  • VALSARTAN 80mg TABLETAS RECUBIERTAS
  • Dosis:
  • 80mg(A7-c)
  • formulario farmacéutico:
  • TABLETA RECUBIERTA
  • Usar para:
  • Humanos
  • Tipo de medicina:
  • medicamento alopático
  • Fabricado por:
  • GENFAR, S.A.

Documentos

Localización

  • Disponible en:
  • VALSARTAN 80mg TABLETAS RECUBIERTAS
    Venezuela
  • Idioma:
  • español

Otros datos

Estado

  • Fuente:
  • Instituto Nacional de Higiene - República Bolivariana de Venezuela
  • Estado de Autorización:
  • VIGENTE
  • Número de autorización:
  • E.F.G.36.616
  • Fecha de autorización:
  • 03-10-2007
  • última actualización:
  • 03-09-2018

Prospecto

,...-~,

r

f

r

J

J

r

Gobierno

Bolivariano

I

Ministerio

del

Roder

Popular

llnstit!Jt9

Nacional

de

H1g1ene

e

Venezuela

para

Ia

Salud

"Rafael

Rangel"

rJ1..

REGISTRO

NACIONAL

DE

PRODUCTOS

FARMACEUTICOS

JR

074640

Caracas,

1 2

NOV

2007

Ciudadana.

DRA.

MARTHA

VILLALBA

DE

HERNANDEZ.

GENFAR

CASA

DE

REPRESENTACIONES

S.A.

Presente.-

acuerdo

dictamen

Junta

Revisora

Productos

Farmaceuticos,

sesi6n

Acta

9057

fecha

03/10/2007,

aprueba

producto

VALSARTAN

80

mg

TABLETAS

RECUBIERTAS

SREF-07-0177.

No.

DE

REGISTRO

E.F.G.

36.616.

Igualmente

informa

dispone

quince

habiles,

para

solicitar

Junta

Revisora

Farmaceuticos,

reconsideraci6n

exigencias

continuaci6n:

(15)

dias

Productos

sefialadas

Compromiso

comunicar

Gremio

Medico

siguiente:

producto

aceptable

siguientes

condiciones

restricciones

uso:

Indicaciones:

Tratamiento

hipertensi6n

arterial

esencial

leve

moderada.

Tratamiento

Insuficiencia

Cardiaca

clase

II-IV.

Posologia:

Hipertensi6n

Arterial:

Adultos:

mg-160

mg/dia.

Insuficiencia

Cardiaca:

cada

horas.

Realizar

ajustes

ascendentes

dosis

hasta

cada

horas,

hasta

dosis

mayor,

tolerada

paciente.

Advertencias:

administre

durante

embarazo

cuando

sospeche

existencia,

durante

lactancia,

menos

criterio

medico

balance

riesgo/beneficio

favorable.

imprescindible

existir

otra

alter-

nativa

terapeutica,

suspendase

definitivamente

lactancia

materna.

Precauciones:

Pacientes

insuficiencia

hepatica

moderada

grave.

pacientes

desequilibrio

hidroelectrolitico,

debe

corregirse

dicha

teraci6n

antes

administraci6n

este

producto.

"2006, ANO BICENTENARIO DEL JURAMENTO DEL GENERALISIMO FRANCISCO DE MIRANDA

Y DE

LA

PARTICIPACION PROTAGONICA Y DEL PODER POPULAR"

.Gobierno

Bolivariano

I

Ministerio

del

Poder Popular

llnstit!Jt~

Nacional

de Venezuela

para

Ia

Salud

de

Hrgrene

"Rafael Rangel"

REGISTRO

NACIONAL

DE

PRODUCTOS

FARMACEUTICOS

E

Realizar

control

frecuente

electrolitos

sericos,

especialmente

potasio,

caso

administraci6n

concomi

tante

suplementos

potasio,

susti

tutos

contienen

potasio

otras

drogas

puedan

ocasionar

hiperpotasemia.

Contraindicaciones:

Hipersensibilidad

componentes

formula.

Cirrosis

hepatica,

colestasis

vias

biliares,

aldostero-

nismo

primario.

Embarazo.

Reacciones

Adversas:

Mareo,

hipotensi6n

ortostatica,

fatiga,

diarrea,

cefalea,

nausea,

insuficiencia

renal,

hiperpotasemia

vertigo.

asigna

producto

periodo

validez

comprobado

(02)

anos

envasado

BLISTER

DE

PVC

-

PVDC

TRANSPARENTE/

FOIL

DE

ALUMINIO,

almacenado

bajo

condiciones

climaticas

Venezuela

(30°C±2°C/70%±5%HR)

Remi

Certi

ficado

Funcionamiento

Representaci6n,

obtenido

registro.

Corregir

texto

empaque

seglin

modelo

anexo.

Corregir

texto

prospecto

interno

segun

modelo

anexo

agregando

condiciones

restricciones

contenidas

este

oficio.

texto

unidad

posol6gica

considera

conforme.

fines

estricto

cumplimiento

Articulo

Reglamento

Ejercicio

Farmacia

vigente,

publicado

Gaceta

Oficial

4.582

extraor-

dinario

fecha

mayo

1993,

informa

estan

obligados

participar

Junta

Revisora

Productos

Farmaceuticos,

fecha

cual

inicie

comercia-

lizaci6n

primer

lote

elaborado,

manera

funcionarios

acreditados

Instituto

Nacional

Higiene

"

Rafael

Rangel

",

puedan

proceder

captar

muestras

correspondientes

propio

fabri-

caci6n,

distribuci6n

caso

productos

importados.

incumplimiento

mencionado

compromiso

sera

sancionado

prohibici6n

producto.

"2006,

ANO BICENTENARIO DEL JURAMENTO DEL GENERAUSIMO FRANCISCO

DE

MIRANDA

Y DE

LA

PARTICIPACION PROTAG6NICA Y DEL PODER POPULAR"

~~Gobierno

Bolivariano

Ministerio del Poder Popular

llnstit~t!=>

Nacional

de Venezuela

para

Salud

H1g1ene

"Rafael Rangel"

REGISTRO

NACIONAL

PRODUCTOS

FARMACEUTICOS

Transcurrido

dicho

lapso

queda

usted

obligaci6n

cumplir

condiciones

bajo

cuales

aprobado

producto.

At

fMB/jh.-

JUNTA

REVISQRA

PRODUCTOS

FARMACEUTICOS

(

\~?:

',~ti~~,\~

.nj's.@·,Q~~RALE:9':

ci.s~rLLO

Pres~dente

·~>

"2006, ANO BICENTENARIO DEL JURAMENTO DEL GENERALISIMO FRANCISCO

MIRANDA

PARTICIPACION PROTAGONICA Y DEL PODER POPULAR"

21-9-2018

Valsartan: EMA revisión de impurezas extendidas a otros medicamentos sartanes

EMA , 20 de septiembre de 2018 La Agencia Europea de Medicamentos (EMA) está ampliando su informe de impurezas en valsartán tras la detección de niveles muy bajos de N-nitrosodietilamina (NDEA) en otra sustancia activa, losartán, hecho por Hetero Labs en India. Como resultado de la detección de esta impureza por parte de las autoridades alemanas, la revisión ahora incluirá medicamentos que contienen otros cuatro "sartanes", a saber, candesartán, irbesartán, losartán y olmesartán.

REDCIMLAC - Red de Centros de Información de Medicamentos de Latinoamérica y el Caribe

13-9-2018

FDA provides update on its ongoing investigation into valsartan products; and reports on the finding of an additional impurity identified in one firm’s already recalled products

FDA provides update on its ongoing investigation into valsartan products; and reports on the finding of an additional impurity identified in one firm’s already recalled products

FDA update on the ongoing investigation into valsartan impurities, recalls and current findings.

FDA - U.S. Food and Drug Administration

13-9-2018

Contaminated valsartan has so far not caused an increased incidence of cancer cases in Denmark

Contaminated valsartan has so far not caused an increased incidence of cancer cases in Denmark

A Danish registry study has examined if the cancer incidence rate is higher among people treated with the blood pressure lowering medicine Valsartan, which due to the risk of contamination was recalled from the market in July 2018. The study concludes that no increased cancer incidence can be seen at present.

Danish Medicines Agency

13-9-2018

Health Canada advises of a second impurity linked to recalled valsartan drugs

Health Canada advises of a second impurity linked to recalled valsartan drugs

OTTAWA - Health Canada is advising Canadians that a second impurity, called N-nitrosodiethylamine (NDEA) has been found in valsartan manufactured by Zhejiang Huahai Pharmaceuticals in China.

Health Canada

10-9-2018

Health Canada updates Canadians on estimates of health risks for recalled valsartan drugs containing NDMA

Health Canada updates Canadians on estimates of health risks for recalled valsartan drugs containing NDMA

OTTAWA –Health Canada is sharing the results of its review of potential long-term health effects involving valsartan drugs that were found to contain the impurity N-nitrosodimethylamine (NDMA). Health Canada scientists have assessed the available data to determine the potential increased risk of developing cancer, to help put the risk into context for Canadians.

Health Canada

22-8-2018

UPDATED: Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Valsartan/Amlodipine/HCTZ, Valsartan/Amlodipine and Valsartan Tablets

UPDATED: Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Valsartan/Amlodipine/HCTZ, Valsartan/Amlodipine and Valsartan Tablets

Torrent Pharmaceuticals Limited is voluntarily recalling ALL LOTS within expiry of Valsartan/Amlodipine/HCTZ, Valsartan/Amlodipine and Valsartan tablets to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Zhejiang Huahai Pharmaceuticals. The impurity detected in the API is N-nitrosodimethylamine (NDMA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industr...

FDA - U.S. Food and Drug Administration

18-8-2018

Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Valsartan / Amlodipine / HCTZ Tablets

Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Valsartan / Amlodipine / HCTZ Tablets

Torrent Pharmaceuticals Limited is voluntarily recalling 14 lots of Valsartan/Amlodipine/HCTZ tablets to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Zhejiang Huahai Pharmaceuticals. The impurity detected in the API is N-nitrosodimethylamine (NDMA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probabl...

FDA - U.S. Food and Drug Administration

9-8-2018

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Valsartan Tablets, USP, 40mg, 80mg, 160mg and 320mg Due to The Detection of Trace Amounts of N-Nitrosodimethylamine (NDMA) Impurity, Found in an Active Pharmaceutical Ingredient (API)

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Valsartan Tablets, USP, 40mg, 80mg, 160mg and 320mg Due to The Detection of Trace Amounts of N-Nitrosodimethylamine (NDMA) Impurity, Found in an Active Pharmaceutical Ingredient (API)

As a precautionary measure, Camber Pharmaceuticals, Inc. is voluntarily recalling all unexpired lots of Valsartan Tablets, USP, 40mg, 80mg, 160mg and 320mg to the hospital, retail and consumer level. This recall of multiple batches of Valsartan Tablets was prompted due to the detection of trace amounts of N-Nitrosodimethylamine (NDMA), a possible process impurity or contaminant in an active pharmaceutical ingredient, manufactured by Hetero Labs Limited, Unit – I (API manufacturer).

FDA - U.S. Food and Drug Administration

19-7-2018

Valsartan-Containing Products: Update Health Professional and Consumer on Recent Recalled Products

Valsartan-Containing Products: Update Health Professional and Consumer on Recent Recalled Products

The investigation into valsartan-containing products is ongoing and there are currently three voluntary recalls related to the NDMA impurity detected in the valsartan

FDA - U.S. Food and Drug Administration

17-7-2018

Teva Pharmaceuticals USA Issues Voluntary Nationwide Recall of Valsartan and Valsartan Hydrochlorothiazide Tablets

Teva Pharmaceuticals USA Issues Voluntary Nationwide Recall of Valsartan and Valsartan Hydrochlorothiazide Tablets

Teva Pharmaceuticals USA today confirmed a voluntary recall to the consumer / user level of 29 lots of single and 51 lots of combination valsartan medicines distributed under the Actavis label in the U.S. due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Zhejiang Huahai Pharmaceutical. The impurity detected in the API is N- nitrosodimethylamine (NDMA), which is a substance that occurs naturally in certain foods, drinking wat...

FDA - U.S. Food and Drug Administration

16-7-2018

Major Pharmaceuticals Issues Voluntary Nationwide Recall of Valsartan Due to The Potential Presence of a Probable Carcinogen (NDMA)

Major Pharmaceuticals Issues Voluntary Nationwide Recall of Valsartan Due to The Potential Presence of a Probable Carcinogen (NDMA)

As a precautionary measure, the distribution firm, Major Pharmaceuticals, is issuing a nationwide voluntary recall of all lots within expiry of Valsartan which were supplied by Teva Pharmaceuticals and labeled as Major Pharmaceuticals.

FDA - U.S. Food and Drug Administration

13-7-2018

Prinston Pharmaceutical Inc Issues Voluntary Nationwide Recall of Valsartan and Valsartan HCTZ Tablets Due to Detection of a Trace Amount of Unexpected Impurity, N-Nitrosodimethylamine (NDMA) in The Products

Prinston Pharmaceutical Inc Issues Voluntary Nationwide Recall of Valsartan and Valsartan HCTZ Tablets Due to Detection of a Trace Amount of Unexpected Impurity, N-Nitrosodimethylamine (NDMA) in The Products

Prinston Pharmaceutical Inc. dba Solco Healthcare LLC. is recalling all lots of Valsartan Tablets, 40 mg, 80mg, 160mg, and 320mg; and Valsartan-Hydrochlorothiazide Tablets, 80mg/12.5mg, 160mg/12.5mg, 160mg/25mg, 320mg/12.5mg, and 320mg/25mg to the retail level. This product recall is due to the detection of a trace amount of an unexpected impurity, N-nitrosodimethylamine (NDMA), made by the manufacturer – Zhejiang Huahai Pharmaceutical Co. Ltd. -- that is used in the manufacture of the subject product ...

FDA - U.S. Food and Drug Administration

13-7-2018

FDA announces voluntary recall of several medicines containing valsartan following detection of an impurity

FDA announces voluntary recall of several medicines containing valsartan following detection of an impurity

FDA is alerting the public about a voluntary recall of several drug products containing valsartan, used to treat high blood pressure and heart failure

FDA - U.S. Food and Drug Administration

9-7-2018

Several drugs containing valsartan being recalled due to contamination with a potential carcinogen

Several drugs containing valsartan being recalled due to contamination with a potential carcinogen

Several drugs containing the ingredient valsartan are being recalled by their manufacturers. An impurity, N-nitrosodimethylamine (NDMA), was found in the valsartan used in these products. The valsartan was supplied by Zhejiang Huahai Pharmaceuticals. NDMA is a potential human carcinogen, which means that it could cause cancer with long-term exposure. Five companies have affected products, which are being recalled (identified in table below).

Health Canada

5-7-2018

Recall of valsartan blood pressure medicine

Recall of valsartan blood pressure medicine

Impurities that could potentially be harmful to health have been found in variants of medicines containing the active substance valsartan. The medicine is used to treat hypertension and heart failure. Patients treated with these medicines are therefore advised to contact their doctor as soon as possible to be switched to another type of medicine.

Danish Medicines Agency

8-3-2012

Review concluded regarding general reimbursement for Valsartan/Hydrochlorothiazide "Actavis"

Review concluded regarding general reimbursement for Valsartan/Hydrochlorothiazide "Actavis"

We have completed our review of an application for general reimbursement for Valsartan/Hydrochlorothiazide "Actavis". The product is neither eligible for general nor general conditional reimbursement.

Danish Medicines Agency

27-6-2018

Copalia HCT (Novartis Europharm Limited)

Copalia HCT (Novartis Europharm Limited)

Copalia HCT (Active substance: amlodipine besylate / valsartan / hydrochlorothiazide) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)4082 of Wed, 27 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/1159/T/67

Europe -DG Health and Food Safety

27-6-2018

Exforge (Novartis Europharm Limited)

Exforge (Novartis Europharm Limited)

Exforge (Active substance: amlodipine / valsartan) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)4085 of Wed, 27 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/716/T/96

Europe -DG Health and Food Safety

27-6-2018

Dafiro HCT (Novartis Europharm Limited)

Dafiro HCT (Novartis Europharm Limited)

Dafiro HCT (Active substance: amlodipine besylate / valsartan / hydrochlorothiazide) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)4084 of Wed, 27 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/1160/T/68

Europe -DG Health and Food Safety

11-6-2018

Exforge HCT (Novartis Europharm Limited)

Exforge HCT (Novartis Europharm Limited)

Exforge HCT (Active substance: amlodipine besylate / valsartan / hydrochlorothiazide) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3752 of Mon, 11 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/1068/T/66

Europe -DG Health and Food Safety

11-6-2018

Dafiro (Novartis Europharm Limited)

Dafiro (Novartis Europharm Limited)

Dafiro (Active substance: amlodipine / valsartan) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3753 of Mon, 11 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/776/T/99

Europe -DG Health and Food Safety

6-6-2018

Copalia (Novartis Europharm Limited)

Copalia (Novartis Europharm Limited)

Copalia (Active substance: amlodipine / valsartan) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3695 of Wed, 06 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/774/T/97

Europe -DG Health and Food Safety

3-5-2018

Entresto (Novartis Europharm Limited)

Entresto (Novartis Europharm Limited)

Entresto (Active substance: sacubitril / valsartan) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)2779 of Thu, 03 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4062/T/18

Europe -DG Health and Food Safety